Breast Cancer Clinical Trial
Ibrance Real World Insights
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments in line with regional licensed indications in real world settings across multiple countries.
Physician inclusion criteria
Oncologist or gynecologist
Responsible for treating a minimum of ≥2-6 (depending on country) ABC/MBC patients who meet the eligibility criteria.
Agrees to participate in the study and complete the eCRFs within the data collection period.
Patient inclusion criteria
≥18 years old.
HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licenced indication(s).
No prior or current enrolment in an interventional clinical trial for ABC/MBC.
Minimum of three months of follow up data since palbociclib with fulvestrant initiation, or minimum of six months of follow up data since palbociclib with letrozole/aromatase inhibitor initiation (core medical record review).
Minimum of three months of follow up data since palbociclib initiation (German interim medical record review only).
Inoperable or recurrent breast cancer (Japan only)
Physician exclusion criteria
Qualified less than 2 years ago or more than 35 years ago
Participated in observational research for ABC/MBC in the last 3 months
Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase inhibitor in line with the licenced indication(s).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10017, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.